IVVD Invivyd, Inc.
Financings ·
Invivyd sold 74,811,404 shares at $0.52 each and pre-funded warrants for up to 21,342,442 more shares, for a total public offering price of $49,997,865.68 before underwriting discounts.
Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, can lend Invivyd up to $30 million in three tranches. Only the first $10 million is open without revenue milestones, and the loans are due March 1, 2029.
Invivyd is a biopharmaceutical company focused on monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. It aims to expand into other high-need indications such as respiratory syncytial virus (RSV) and measles. Its first authorized mAb, PEMGARDA (pemivibart), received an emergency use authorization from the FDA in March 2024 for pre-exposure prophylaxis of COVID-19 in adults and adolescents with moderate-to-severe immune compromise. Its next-generation candidate, VYD2311, was engineered from adintrevimab, and positive full Phase 1/2 data were announced in June 2025. The FDA granted Fast Track designation for VYD2311 for prevention of COVID-19 in people with underlying risk factors for progression to severe disease. The Phase 3 DECLARATION trial began in December 2025, with top-line data anticipated in mid-2026. In February 2026 the company announced FDA alignment on the Phase 3 LIBERTY trial, which tests VYD2311 alone and with an mRNA COVID vaccine. It also selected VBY329, a candidate for RSV prevention in neonates, infants and children, in November 2025, and relies on WuXi Biologics as its contract manufacturer for chemistry, manufacturing and controls work.
| Product or program | What it is | Stage |
|---|---|---|
| PEMGARDA (pemivibart) | Monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised people | Emergency use authorized, March 22, 2024 |
| VYD2311 | Next-generation COVID-19 monoclonal antibody for prevention | Phase 3 DECLARATION started December 2025; Fast Track designation |
| LIBERTY trial (VYD2311) | VYD2311 alone and with an mRNA COVID vaccine | Phase 3; FDA alignment announced February 2026 |
| VBY329 | Monoclonal antibody for RSV prevention in neonates, infants and children | Selected November 2025; IND readiness targeted second half of 2026 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $53.4 million | $25.4 million |
| Research and development | $38.3 million | $137.3 million |
| Net income (loss) | -$52.5 million | -$169.9 million |
| Cash from operations | -$58.1 million | -$170.5 million |
| Cash and equivalents | $226.7 million | $69.3 million |
Our latest story on this, dated Aug 20, 2025: "Invivyd prices offering of 74,811,404 shares at $0.52 each". The story links the filing or release it is based on. Read the story.
Invivyd, Inc. trades under the ticker IVVD on NASDAQ.
Invivyd, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Invivyd, Inc. is 1832038. Its filings are on SEC EDGAR.
294,758,746 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Invivyd, Inc. under United States.
Our directory classifies Invivyd, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Invivyd, Inc. is US00534A1025.
aibio.space lists Invivyd, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Invivyd is a biopharmaceutical company focused on monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. It aims to expand into other high-need indications such as respiratory syncytial virus (RSV) and measles.
PEMGARDA (pemivibart): Monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised people Stage: Emergency use authorized, March 22, 2024.
VYD2311: Next-generation COVID-19 monoclonal antibody for prevention Stage: Phase 3 DECLARATION started December 2025; Fast Track designation.
$53.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Invivyd, Inc. reported a net loss of $52.5 million for the fiscal year ended Dec 31, 2025, and used $58.1 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio